| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Although, examples of all oxadiazole isomers are known, only the biotransformation pathways of compounds containing 1,2,4-oxdiazole rings have been reported so far. (A15200) |
|---|---|
| Toxicity/Toxicokinetics |
Toxicity Summary
'Oxadiazon is a member of the oxadiazole class of herbicides. While current data are limited, EPA has evidence that compounds within a class may share a common mechanism of toxicity. At this time, the Agency does not have sufficient data concerning common mechanism issues to determine whether or not oxadiazon shares a common mechanism of toxicity with other substances, including other oxadiazoles or other probable human carcinogens.' (L2081) Toxicity Data LC50 (rat) > 200,000 mg/m3 LD50 >5000 mg/kg (oral, rat) (L2081); LD50 >2000 mg/kg (dermal, rabbit) (L2081); LC50 >1.94 mg/L (inhalation, rat) (L2081) Non-Human Toxicity Values LD50 Rat oral (acute) >3,500 mg/kg LD50 Rat oral >5000 mg/kg LD50 Rat percutaneous >2000 mg/kg |
| Additional Infomation |
Oxadiazon can cause cancer according to an independent committee of scientific and health experts. It can cause developmental toxicity according to The Environmental Protection Agency (EPA).
Oxydiazon is a crystalline solid. Used as an herbicide. Oxadiazon is an aromatic ether. Oxadiazon is used as pre-emergence and post-emergence herbicide. It is mainly used for cotton, rice, soybean and sunflower and acts by inhibiting protoporphyrinogen oxidase (PPO). |
| Molecular Formula |
C15H18CL2N2O3
|
|---|---|
| Molecular Weight |
345.22
|
| Exact Mass |
344.069
|
| CAS # |
19666-30-9
|
| PubChem CID |
29732
|
| Appearance |
White crystals
Colorless crystals |
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
417.0±55.0 °C at 760 mmHg
|
| Melting Point |
88-90°C
|
| Flash Point |
206.0±31.5 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.569
|
| LogP |
4.55
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
22
|
| Complexity |
462
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1OC(C(C)(C)C)=NN1C2=CC(OC(C)C)=C(Cl)C=C2Cl
|
| InChi Key |
CHNUNORXWHYHNE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H18Cl2N2O3/c1-8(2)21-12-7-11(9(16)6-10(12)17)19-14(20)22-13(18-19)15(3,4)5/h6-8H,1-5H3
|
| Chemical Name |
5-tert-butyl-3-(2,4-dichloro-5-propan-2-yloxyphenyl)-1,3,4-oxadiazol-2-one
|
| Synonyms |
G-315; G 315; Oxadiazon
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 50 mg/mL (~144.84 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.24 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (7.24 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.24 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8967 mL | 14.4835 mL | 28.9670 mL | |
| 5 mM | 0.5793 mL | 2.8967 mL | 5.7934 mL | |
| 10 mM | 0.2897 mL | 1.4484 mL | 2.8967 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
